Most recent by Maria Fleseriu, MD, FACE
VIDEO: Data shed new light on treatments for acromegaly, Cushing’s disease
BOSTON — In this video exclusive, Maria Fleseriu, MD, FACE, discusses some of the top adrenal and pituitary news from ENDO 2024.
Once-monthly octreotide provides sustained acromegaly control with fewer injections
BOSTON — Adults with acromegaly previously controlled with standard of care experienced similar disease control with once-monthly injectable octreotide at 24 and 52 weeks, with no serious adverse events, data presented at ENDO 2024 show.
VIDEO: Primary aldosterone screening, AI among adrenal topics presented at ENDO 2023
CHICAGO—In this video exclusive, Maria Fleseriu, MD, FACE, and Adina Turcu, MD, MS, talk about research on adrenal disorders presented at ENDO 2023, including artificial intelligence and a debate about which patients to screen for primary aldosteronism.
VIDEO: Pituitary and adrenal research highlights from ECE 23
In this video exclusive, Maria Fleseriu, MD, FACE, reviews the pituitary and adrenal research highlights presented at ECE 2023, the annual meeting of the European Society of Endocrinology, which took place in Istanbul, Turkey, in May.
VIDEO: New Cushing’s, acromegaly drug data prominent at ENDO annual meeting
ATLANTA — In this video exclusive, Maria Fleseriu, MD, FACE, reviews the pituitary research presented at the annual meeting of the Endocrine Society in Atlanta.
Thyroid dysfunction highly prevalent in Cushing’s syndrome
Central hypothyroidism is prevalent in about 1 in 2 adults with Cushing’s syndrome, and thyroid function can be restored after curative surgery for most patients, according to study findings.